Dec 16, 2019 3:15pm EST Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study
Dec 11, 2019 4:05pm EST Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL
Dec 10, 2019 7:00am EST Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia
Dec 3, 2019 7:00am EST Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Nov 26, 2019 4:05pm EST Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD
Nov 25, 2019 4:05pm EST Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference
Nov 21, 2019 8:00am EST Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia
Nov 20, 2019 4:05pm EST Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder